Morepen Laboratories has announced the launch of four new products – Ticapen, UdoFix, LycoMore, Acifix in the month of April 2025 to cater the domestic market in addition to Empamore launched last month.

Ticapen (Ticagrelor 60mg/90mg) is a clinically proven, affordable antiplatelet therapy indicated for Acute Coronary Syndrome (ACS), Angina, and Myocardial Infarction (MI). It is manufactured in USFDA-approved facilities and comes in a unique 4x14 patient-compliant pack featuring day/night adherence markers and premium matte foil packaging.

“UdoFix (Ursodeoxycholic Acid 150/300mg) redefines hepatoprotective therapy with 98.23 percent superior dissolution, anti-counterfeit Holosec packaging, and manufacturing in a USFDA-certified facility,” said the company in a statement.

It further added that LycoMore Syrup combines Lycopene with essential vitamins and minerals to support immunity and overall recovery. Acifix Raft Suspension delivers fast, targeted relief for GERD, reflux, and heartburn.

“These new launches reflect our unwavering focus on research-led innovation, clinical excellence, and affordable healthcare access, addressing critical needs in cardiology, hepatology, nutrition, and diabetology,” it said.

This strategic expansion reinforces Morepen's commitment to scaling its finished dosages business while continuing to invest in cutting-edge R&D that powers a robust pipeline of differentiated, high-quality medicines.

“Importantly, all APIs used in these products are manufactured in-house by Morepen at its USFDA-approved plants, ensuring consistent quality and supply chain control,” it said.

As exporter of APIs for six globally used molecules – Loratadine, Montelukast, Desloratadine, Atorvastatin, Rosuvastatin, and Fexofenadine, Morepen has a presence in 82 countries, backed by an annual API manufacturing capacity of 144 metric tons.

“Its integrated capabilities across the pharmaceutical value chain give it a unique competitive edge in both regulated and emerging markets like the US, Europe, Japan, China, and Russia,” it said.

With a current formulation business size of approximately INR 325 crore, the company is now accelerating toward an INR 1,000 crore target over the next five years-driven by deeper market penetration, an expanded field force, and a growing portfolio of cost-efficient, globally compliant therapies.